All News #Library
Others
Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial o
05 Jun 2025 //
PR NEWSWIRE
Mediar begins patient dosing in US FDA approved phase 1 trial of MTX-463
07 May 2024 //
PHARMABIZ
With $105M and Big Pharma backing, Mediar takes aim at fibrosis
15 Mar 2023 //
FIERCE BIOTECH
Pfizer-backed Mediar Therapeutics ropes in another Big Pharma investor
05 Dec 2022 //
ENDPTS
Simon Sturge Joins Mediar Therapeutics as Executive Chairman
15 Sep 2021 //
BUSINESSWIRE

Market Place
Sourcing Support